Cargando…
Tumor penetrating nanomedicine targeting both an oncomiR and an oncogene in pancreatic cancer
Developing new targeted therapy for pancreatic cancer is one of the major current challenges in cancer research. KRAS mutations and miRNA dysregulation (e.g. miR-21-5p oncomiR) play key roles in Pancreatic Ductal Adenocarcinoma (PDAC), leading to rapid progression of the disease. As the KRAS mutatio...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731108/ https://www.ncbi.nlm.nih.gov/pubmed/31523393 http://dx.doi.org/10.18632/oncotarget.27160 |